IPCALAB

Ipca Laboratories Share Price

 

 

Invest in Ipca Laboratories with 3.27X leverage

Invest with MTF

Performance

  • Low
  • ₹1,506
  • High
  • ₹1,574
  • 52 Week Low
  • ₹1,168
  • 52 Week High
  • ₹1,710
  • Open Price₹1,574
  • Previous Close₹1,575
  • Volume320,103
  • 50 DMA₹1,422.61
  • 100 DMA₹1,404.00
  • 200 DMA₹1,399.57

Investment Returns

  • Over 1 Month + 5.14%
  • Over 3 Month + 15.97%
  • Over 6 Month + 6.76%
  • Over 1 Year -5.19%

Smart Investing Starts Here Start SIP with Ipca Laboratories for Steady Growth!

Invest Now

Ipca Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 46.1
  • PEG Ratio
  • 1.8
  • Market Cap Cr
  • 38,345
  • P/B Ratio
  • 5.2
  • Average True Range
  • 49.17
  • EPS
  • 39.02
  • Dividend Yield
  • 0.1
  • MACD Signal
  • 11.71
  • RSI
  • 71.09
  • MFI
  • 79.84

Ipca Laboratories Financials

Ipca Laboratories Technicals

EMA & SMA

Current Price
₹1,511.40
-63.6 (-4.04%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,455.54
  • 50 Day
  • ₹1,422.61
  • 100 Day
  • ₹1,404.00
  • 200 Day
  • ₹1,399.57

Resistance and Support

1559.63 Pivot Speed
  • R3 1,659.27
  • R2 1,620.93
  • R1 1,597.97
  • S1 1,536.67
  • S2 1,498.33
  • S3 1,475.37

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Ipca Laboratories Ltd. is a global pharmaceutical company, producing over 350 formulations and 80 APIs. Operating in 120+ countries, it leads in therapeutic areas like pain, rheumatology, and antimalarials, with fully-automated facilities approved by global regulatory bodies.

Ipca Laboratories has an operating revenue of Rs. 9,357.41 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 13% is healthy, ROE of 10% is good. The company has a reasonable debt to equity of 8%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 10% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 12% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 49 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Ipca Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-11 Quarterly Results
2025-05-29 Audited Results & Final Dividend
2025-02-13 Quarterly Results
2024-11-14 Quarterly Results & Interim Dividend
Date Purpose Remarks
2025-08-05 FINAL Rs.2.00 per share(200%)Final Dividend
2024-11-25 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2023-11-22 INTERIM Rs.2.00 per share(200%)Interim Dividend (Revised)
2022-11-23 INTERIM Rs.4.00 per share(400%)Interim Dividend
2021-11-23 INTERIM Rs.8.00 per share(400%)Interim Dividend
View Ipca Laboratories Dividend History Arrow
Date Purpose Remarks
2022-01-11 Split Rs.0.00 split from Rs. 2/- to Re. 1/-.

Ipca Laboratories F&O

Ipca Laboratories Shareholding Pattern

44.72%
30.04%
5.99%
10.42%
0%
6.55%
2.28%

About Ipca Laboratories

  • NSE Symbol
  • IPCALAB
  • BSE Symbol
  • 524494
  • Managing Director & CFO
  • Mr. Ajit Kumar Jain
  • ISIN
  • INE571A01038

Similar Stocks to Ipca Laboratories

Ipca Laboratories FAQs

Ipca Laboratories share price is ₹1,511 As on 12 January, 2026 | 10:05

The Market Cap of Ipca Laboratories is ₹38344.9 Cr As on 12 January, 2026 | 10:05

The P/E ratio of Ipca Laboratories is 46.1 As on 12 January, 2026 | 10:05

The PB ratio of Ipca Laboratories is 5.2 As on 12 January, 2026 | 10:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23